Earnings Report

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements

Stock market news /

Zevra Therapeutics, Inc. (ZVRA) reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth and continued progress in its rare disease pipeline. The company posted **net product revenue of $15.2 million** for Q4 2025, primarily driven by robust sales of its attention-deficit/hyperactivity disorder (ADHD) treatment, **AZSTARYS®**. […]

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements Read More »

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance

Stock market news /

Key Takeaways Atea Pharmaceuticals, Inc. (ATAI) reported Q4 2025 revenue of $125 million, surpassing analyst consensus of $118 million, per the company’s earnings call presentation. Non-GAAP diluted earnings per share (EPS) reached $0.15, exceeding expectations of $0.10, according to internal company financial statements. The company initiated a Phase 3 clinical trial for its novel antiviral

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance Read More »

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments

Stock market news /

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments Key Takeaways D-Wave Quantum Inc. (QBTS) announced Q4 2025 revenue of $5.8 million, marking a robust 35% increase year-over-year, primarily driven by strong performance in its cloud and professional services segments, per the Q4 2025 Earnings Call Transcript. Total bookings for the quarter reached $6.5

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments Read More »

$VRTX Earnings Report Scheduled for February 12

Stock market news /

Vertex Pharmaceuticals ($VRTX), the biotechnology giant renowned for its transformative cystic fibrosis (CF) therapies, is set to report its latest quarterly earnings on February 12. This highly anticipated announcement will offer critical insights into the company’s financial health, the sustained performance of its market-leading CF drugs, and the progress of its expansive pipeline targeting severe

$VRTX Earnings Report Scheduled for February 12 Read More »